Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SKBBY · Chengdu, China
Works in Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a clinical trial sponsor based in Chengdu, China, listed as SKBBY. It has 44 active clinical trials with 9,290 planned participants, across 11 therapeutic areas. Since 2021 it has completed 9 trials and stopped 2 early.
Trial track record · since 2021
Financials · SKBBY
Pipeline · 44 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd is lead sponsor of 44 active clinical trials on ClinicalTrials.gov, with 9,290 planned participants, in Dermatology, ENT, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 9 trials and stopped 2 early.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd is based in Chengdu, China and is listed as SKBBY. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-21.
Approve Suite is not affiliated with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.